FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma
It was evaluated in DREAMM-2 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp
It was intended for the treatment of blastic plasmacytoid dendritic cell neoplasm
Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI
The results of INSPIRE study
BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority of BRAFV600 Mutated Cancers
Results of the NCI-MATCH Trial Subprotocol H
EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide
Arsenic trioxide medac is a generic of Trisenox which has been authorised in the EU since 2002
FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL
Efficacy of tafasitamab-cxix with lenalidomide was evaluated in L-MIND study
EMA Recommends Granting a Marketing Authorisation for Equidacent
Biosimilar bevacizumab received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and cervical carcinoma
Conducting Phase I Clinical Trials During the COVID-19 Pandemic
An experience of the Drug Development Department of the Gustave Roussy
TP53 Allelic State is Critical in Myelodysplastic Syndromes
Big analysis delineated two subsets of patients with distinct phenotypes and outcomes
FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic Melanoma
Efficacy was investigated in the IMspire150 study
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
Approval is based on the findings from the ZUMA-2 trial
EMA Recommends Granting a Marketing Authorisation for Acalabrutinib
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is intended for the treatment of chronic lymphocytic leukaemia